This study is testing a new drug called IDE161 for people with advanced solid tumors. Tumors are lumps or masses of abnormal cells. The study checks if the drug is safe, how well it works, and how the body processes it. Participants need to have specific genetic changes in their tumors, which make them suitable for this study. These changes affect how cells repair themselves, known as the homologous recombination (HR) pathway. People who join must be 18 or older, have tumors that are advanced or spread, and have tried other treatments first.

• The study may involve multiple visits to the clinic for tests and check-ups.
• Participants need to stop certain treatments before joining the study.
• Compensation is not specified, but you should discuss this with the study team.